The strong beat and raised guidance, combined with positive Adjusted EBITDA and accelerating Optune Pax adoption, signal a fundamental inflection in Novocure's commercial trajectory. Traders should watch for continued prescription momentum for Optune Pax and the upcoming FDA decision on TTFields for brain metastases from NSCLC (Q4 2026), which could be a major catalyst. The stock may gap up on this report; consider taking profits into strength given the stock's history of volatile post-earnings moves.
Price Chart
Executive Summary
Novocure reported Q2 2026 net revenues of $183.6M (+16% YoY), beating consensus of $172.4M, and a GAAP EPS loss of $0.13, significantly beating the consensus estimate of -$0.33. The company raised its full-year 2026 revenue guidance to $710M-$725M (from $690M-$710M) and its Adjusted EBITDA guidance to $0M-$15M (from -$15M-$0M), driven by record active patient growth of 18% YoY and strong adoption of Optune Pax (285 active patients, up from 83 in Q1). The net loss narrowed sharply to $15.7M from $40.1M in the prior year, and the company achieved positive Adjusted EBITDA of $10.8M, a key milestone on its path to profitability. This is a clear beat on both top and bottom lines with raised guidance, indicating accelerating commercial momentum and improving operating leverage.
Key Financial Metrics
Key Facts
- Q2 2026 net revenue of $183.6M, up 16% YoY vs $158.8M, beating consensus of $172.4M
- GAAP EPS loss of $0.13, beating consensus estimate of -$0.33 by 60.8%
- Full-year 2026 revenue guidance raised to $710M-$725M from $690M-$710M
- Full-year 2026 Adjusted EBITDA guidance raised to $0M-$15M from -$15M-$0M
- Record 5,128 total active patients on TTFields therapy globally, up 18% YoY
- Optune Pax active patients surged to 285 from 83 at end of Q1 2026
- Net loss narrowed to $15.7M from $40.1M in Q2 2025
- Achieved positive Adjusted EBITDA of $10.8M vs -$9.9M in Q2 2025
- Gross margin improved to 78% from 74% in prior year, aided by a $4.9M tariff refund
- CE Mark received for Optune Pax in EU, with Germany as first launch market
Financial Impact
Revenue beat consensus by $11.2M (6.5%); EPS beat consensus by $0.20 (60.8%); guidance raised by $20M at midpoint
Risk Factors
- Optune Pax launch is still early and reimbursement expansion in EU is uncertain
- FDA decision on brain metastases indication is binary and could be delayed
- Company remains GAAP net loss-making, though narrowing
- One-time tariff refund of $4.9M boosted gross margin and may not recur
- Competitive landscape in GBM and pancreatic cancer could evolve
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001645113-26-000063 |
| Document: nvcr-20260723.htm | 0001645113-26-000063 |
| Document: 0001645113-26-000063-index-headers.html | 0001645113-26-000063 |
| Document: 0001645113-26-000063-index.html | 0001645113-26-000063 |
| Document: 0001645113-26-000063.txt | 0001645113-26-000063 |
| 8-K Data (Synthetic) | 0001645113-26-000063 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 23d ago | 8-K | $15.63 $16.38 | ▲ +4.80% | ▲ +5.13% | $14.94 (−4.41%) |
Sep 1, 2026 4w ago | 8-K | $17.38 $15.63 | ▼ −10.07% | ▼ −10.15% | $14.94 (−14.04%) |
Jul 23, 2026 10w ago | 8-K | $19.99 $15.23 | ▼ −23.81% | ▼ −24.29% | $14.94 (−25.26%) |
Jun 30, 2026 13w ago | 8-K | $15.15 $17.32 | ▲ +14.32% | ▲ +13.72% | $14.94 (−1.39%) |
Jun 18, 2026 15w ago | 8-K | $14.28 $15.05 | ▼ −5.39% | ▼ −7.06% | $14.94 (−4.62%) |
Jun 5, 2026 17w ago | 8-K | $16.85 $17.60 | ▲ +4.45% | ▲ +2.34% | $14.94 (−11.34%) |
Jun 3, 2026 17w ago | Insider Cluster | $17.99 $17.71 | ▼ −1.56% | ▲ +1.00% | $14.94 (−16.95%) |
Jun 3, 2026 17w ago | Insider Cluster | $17.99 $17.71 | ▼ −1.56% | ▲ +1.00% | $14.94 (−16.95%) |
Apr 20, 2026 23w ago | DEFA14A | $12.23 $12.12 | ▼ −0.90% | ▼ −1.98% | $14.94 (+22.16%) |
Feb 27, 2026 31w ago | Insider Cluster | $13.67 $13.04 | ▼ −4.61% | ▼ −2.63% | $14.94 (+9.29%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access